The emergence of multidrug-resistant (MDR) bacterial infections poses a catastrophic threat to medicine. The development of phage-based therapy combined with antibiotics might be an advantageous weapon in the arms race between human and MDR bacteria. A cocktail composed of the MDR Acinetobacter baumannii infecting bacteriophages with high lytic activity was used in combination with antibiotics to destroy a bacterial biofilm in human urine. A. baumannii exhibited varying susceptibility to the host range of bacteriophages used in this study, ranging from 56% to 84%. This study demonstrated that bacteriophages could reduce biofilm biomass in a human urine model, and some of the antibiotics commonly used in the treatment of urinary tract infection (UTI) act synergistically with phage cocktails. Additionally, the combined treatment showed a significantly greater reduction of biofilm biomass and clearance of persister cells.
Get full access to this article
View all access options for this article.
References
1.
MorrisF.C., DexterC., KostouliasX., UddinM.I, and PelegA.Y. 2019. The mechanisms of disease caused by Acinetobacter baumannii. Front. Microbiol. 10:1601.
2.
Di VenanzioG., Flores-MirelesA.L, CalixJ.J, HauratM.F, ScottN.E, PalmerL.D, PotterR.F, HibbingM.E, FriedmanL., WangB., DantasG., SkaarE.P, HultgrenS.J, and FeldmanM.F.. 2019. Urinary tract colonization is enhanced by a plasmid that regulates uropathogenic Acinetobacter baumannii chromosomal genes. Nat. Commun. 10:1–13.
3.
LoodR., WinerB.Y, PelzekA.J, Diez-MartinezR., ThandarM., EulerC.W, SchuchR., and FischettiV.A.. 2015. Novel phage lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model. Antimicrob. Agents Chemother. 59:1983–1991.
4.
SpellbergB., and BonomoR.A.. 2015. Combination therapy for extreme drug-resistant Acinetobacter baumannii: ready for prime time? Crit. Care Med. 43:1332–1334.
5.
JacobsenS.M., SticklerD.J, MobleyH.L.T, and ShirtliffM.E.. 2008. Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis. Clin. Microbiol. Rev. 21:26–59.
6.
CorteseY.J., WagnerV.E, TierneyM., DevineD., and FogartyA.. 2018. Review of catheter-associated urinary tract infections and in vitro urinary tract models. J. Healthc. Eng. 2018:1–16.
7.
VranicS., ZatricN., RebicV., AljicevicM., and AbdulzaimovicA.. 2017. The most frequent isolates from outpatients with urinary tract infection. Mater. Sociomed. 29:17.
8.
AsifM., AlviI.A, and Ur RehmanS.. 2018. Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infect. Drug Resist. 11:1249–1260.
9.
MisicD., AsaninJ., SpergserJ., SzostakM., and LoncaricI.. 2018. OXA-72-mediated carbapenem resistance in sequence type 1 multidrug colistin-resistant Acinetobacter baumannii associated with urinary tract infection in a dog from Serbia. Antimicrob. Agents Chemother. 62:e00219-18.
10.
WongD., NielsenT.B, BonomoR.A, PantapalangkoorP., LunaB., and SpellbergB.. 2017. Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges. Clin. Microbiol. Rev. 30:409–447.
11.
OleksiukL.M., NguyenM.H, PressE.G, UpdikeC.L, O'HaraJ.A, DoiY., ClancyC.J, and ShieldsR.K.. 2014. In vitro responses of Acinetobacter baumannii to two- and three-drug combinations following exposure to colistin and doripenem. Antimicrob. Agents Chemother. 58:1195–1199.
12.
DincG., DemiraslanH., ElmaliF., AhmedS.S, AlpE., and DoganayM.. 2015. Antimicrobial efficacy of doripenem and its combinations with sulbactam, amikacin, colistin, tigecycline in experimental sepsis of carbapenem-resistant Acinetobacter baumannii. New Microbiol. 38:67–73.
13.
JeonJ., RyuC.M, LeeJ.Y, ParkJ.H, YongD., and LeeK.. 2016. In vivo application of bacteriophage as a potential therapeutic agent to control OXA-66-like carbapenemase-producing Acinetobacter baumannii strains belonging to sequence type 357. Appl. Environ. Microbiol. 82:4200–4208.
14.
ThandarM., LoodR., WinerB.Y, DeutschD.R, EulerC.W, and FischettiV.A.. 2016. Novel engineered peptides of a phage lysin as effective antimicrobials against multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 60:2971–2979.
15.
BlascoL., AmbroaA., LopezM., Fernandez-GarciaL., BleriotI., TrastoyR., Ramos-VivasJ., CoenyeT., Fernandez-CuencaF., VilaJ., Martinez-MartinezL., Rodriguez-BañoJ., PascualA., CisnerosJ.M, PachonJ., BouG., and TomasM.. 2019. Combined use of the Ab105-2φΔCI lytic mutant phage and different antibiotics in clinical isolates of multi-resistant Acinetobacter baumannii. Microorganisms, 7:556.
16.
GrygorcewiczB., Chajecka-WierzchowskaW., AugustyniakA., WasakA., StachurskaX., NawrotekP., and DołęgowskaB.. 2019. In-milk inactivation of Escherichia coli O157: H7 by the environmental lytic bacteriophage ECPS-6. J. Food Saf. 40:e12747.
TagliaferriT.L., JansenM., and HorzH.-P.P. 2019. fighting pathogenic bacteria on two fronts: phages and antibiotics as combined strategy. Front. Cell. Infect. Microbiol. 9:22.
19.
ThummeepakR., KittiT., KunthalertD., and SitthisakS.. 2016. Enhanced antibacterial activity of Acinetobacter baumannii bacteriophage ØABP-01 endolysin (LysABP-01) in combination with colistin. Front. Microbiol. 7:1–8.
20.
Clinical and Laboratory Standards Institute (CLSI). 2015. Performance Standards for Antimicrobial Susceptibility Testing; 25th Informational Supplement. CLSI Document M100-S25, Clinical and Laboratory Standards Institute, Wayne, PA.
21.
GuzmánC., JofreJ., BlanchA.R, and LucenaF.. 2007. Development of a feasible method to extract somatic coliphages from sludge, soil and treated biowaste. J. Virol. Methods, 144:41–48.
22.
TurnerD., WandM.E, BriersY., LavigneR., SuttonJ.M, and ReynoldsD.M.. 2017. Characterisation and genome sequence of the lytic Acinetobacter baumannii bacteriophage vB_AbaS_Loki. PLoS One, 12:e0172303.
23.
MirzaeiM.K., and NilssonA.S.. 2015. Isolation of phages for phage therapy: a comparison of spot tests and efficiency of plating analyses for determination of host range and efficacy. PLoS One, 10:e0118557.
24.
ŁubowskaN., GrygorcewiczB., Kosznik-KwaśnickaK., Zauszkiewicz-PawlakA., WęgrzynA., DołęgowskaB., and PiechowiczL.. 2019. Characterization of the three new kayviruses and their lytic activity against multidrug-resistant Staphylococcus aureus. Microorganisms. 7:471.
25.
SzymczakM., GrygorcewiczB., Karczewska-GolecJ., DecewiczP., PankowskiJ.A, Országh-SzturoH., BącalP., DołęgowskaB., and GolecP.. 2020. Characterization of a Unique Bordetella bronchiseptica vB_BbrP_BB8 Bacteriophage and Its Application as an Antibacterial Agent. Int. J. Mol. Sci. 21:1403.
26.
Chajęcka-WierzchowskaW., ZadernowskaA., and Ł. Łaniewska-Trokenheim. 2016. Virulence factors, antimicrobial resistance and biofilm formation in Enterococcus spp. isolated from retail shrimps. LWT Food Sci. Technol. 69:117–122.
27.
StepanovićS., VukovićD., HolaV., Di BonaventuraG., DjukićS., I. Ćirković, and RuzickaF.. 2007. Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. APMIS, 115:891–899.
28.
SkogmanM.E., VuorelaP.M, and FallareroA.. 2012. Combining biofilm matrix measurements with biomass and viability assays in susceptibility assessments of antimicrobials against Staphylococcus aureus biofilms. J. Antibiot. (Tokyo), 65:453–459.
29.
Van TwestR., and KropinskiA.M.. 2009. Bacteriophage Enrichment from Water and Soil. In: M.R. Clokie and A.M. Kropinski (eds.), Bacteriophages. Methods in Molecular Biology™, vol. 501. Humana Press, Clifton,, NJ, pp. 15–21.
30.
AugustyniakA., GrygorcewiczB., and NawrotekP.. 2018. Isolation of multidrug resistant coliforms and their bacteriophages from swine slurry. Turkish J. Vet. Anim. Sci. 42:319–325.
SchooleyR.T., BiswasB., GillJ.J, Hernandez-MoralesA., LancasterJ., LessorL., BarrJ.J, ReedS.L, RohwerF., BenlerS., SegallA.M, TaplitzR., SmithD.M, KerrK., KumaraswamyM., NizetV., LinL., McCauleyM.D, StrathdeeS.A, BensonC.A, PopeR.K, LerouxB.M, PicelA.C, MateczunA.J, CilwaK.E, RegeimbalJ.M, EstrellaL.A, WolfeD.M, HenryM.S, QuinonesJ., SalkaS., Bishop-LillyK.A, YoungR., and HamiltonT.. 2017. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob. Agents Chemother. 61:e00954-17.
34.
LaVergneS., HamiltonT., BiswasB., KumaraswamyM., SchooleyR.T, and WootenD.. 2018. Phage therapy for a multidrug-resistant Acinetobacter baumannii craniectomy site infection. Open Forum Infect. Dis. 5:ofy064.
35.
YangH., LiangL., LinS., and JiaS.. 2010. Isolation and characterization of a virulent bacteriophage AB1 of Acinetobacter baumannii. BMC Microbiol. 10:131.
36.
GorskiA., MiedzybrodzkiR., BorysowskiJ., Weber-DabrowskaB., LobockaM., FortunaW., LetkiewiczS., ZimeckiM., and FilbyG.. 2009. Bacteriophage therapy for the treatment of infections. Curr. Opin. Investig. Drugs, 10:766–774.
37.
HughesK.A., SutherlandI.W, ClarkJ., and JonesM.V.. 1998. Bacteriophage and associated polysaccharide depolymerases—novel tools for study of bacterial biofilms. J. Appl. Microbiol. 85:583–590.
38.
AlvesD.R., Perez-EstebanP., KotW., BeanJ.E, ArnotT., HansenL.H, EnrightM.C, and JenkinsA.T.A. 2016. A novel bacteriophage cocktail reduces and disperses Pseudomonas aeruginosa biofilms under static and flow conditions. Microb. Biotechnol. 9:61–74.
39.
SegallA.M., RoachD.R, and StrathdeeS.A.. 2019. Stronger together? Perspectives on phage-antibiotic synergy in clinical applications of phage therapy. Curr. Opin. Microbiol. 51:46–50.
ChaudhryW.N., Concepcion-AcevedoJ., ParkT., AndleebS., BullJ.J, LevinB.R, Concepción-AcevedoJ., ParkT., AndleebS., BullJ.J, and LevinB.R.. 2017. Synergy and order effects of antibiotics and phages in killing pseudomonas aeruginosa biofilms. PLoS One, 12:e0168615.
43.
Kirby, A.E. 2012. Synergistic Action of Gentamicin and Bacteriophage in a Continuous Culture Population of Staphylococcus aureus. PLoS One, 7:e51017.
44.
PletzerD., MansourS.C, and HancockR.E.W. 2018. Synergy between conventional antibiotics and anti-biofilm peptides in a murine, sub-cutaneous abscess model caused by recalcitrant ESKAPE pathogens. PLoS Pathog. 14.
BediM.S., VermaV., and ChhibberS.. 2009. Amoxicillin and specific bacteriophage can be used together for eradication of biofilm of Klebsiella pneumoniae B5055. World J. Microbiol. Biotechnol. 25:1145–1151.
47.
KumaranD., TahaM., YiQ.L, Ramirez-ArcosS., DialloJ.S, CarliA., and AbdelbaryH.. 2018. Does treatment order matter? Investigating the ability of bacteriophage to augment antibiotic activity against Staphylococcus aureus biofilms. Front. Microbiol. 9:127.
48.
AnderssonD.I., and HughesD.. 2014. Microbiological effects of sublethal levels of antibiotics. Nat. Rev. Microbiol. 12:465–478.
49.
RabanalF., and CajalY.. 2017. Recent advances and perspectives in the design and development of polymyxins. Nat. Prod. Rep. 34:886–908.
50.
KimM., JoY., HwangY.J, HongH.W, HongS.S, ParkK., and MyungH.. 2018. Phageantibiotic synergy via delayed lysis. Appl. Environ. Microbiol. 84:e02085-18.
51.
PourN.K., DusaneD.H, DhakephalkarP.K, ZaminF.R, ZinjardeS.S, and ChopadeB.A.. 2011. Biofilm formation by Acinetobacter baumanniistrains isolated from urinary tract infection and urinary catheters. FEMS Immunol. Med. Microbiol. 62:328–338.
52.
Danis-WlodarczykK., VandenheuvelD., Bin JangH., BriersY., OlszakT., ArabskiM., WasikS., DrabikM., HigginsG., TyrrellJ., HarveyB.J, NobenJ.-P, LavigneR., and Drulis-KawaZ.. 2016. A proposed integrated approach for the preclinical evaluation of phage therapy in Pseudomonas infections. Sci. Rep. 6:28115.
53.
JansenM., WahidaA., LatzS., KrüttgenA., HäfnerH., BuhlE.M, RitterK., and HorzH.-P.. 2018. Enhanced antibacterial effect of the novel T4-like bacteriophage KARL-1 in combination with antibiotics against multi-drug resistant Acinetobacter baumannii. Sci. Rep. 8:14140.
54.
SatoY., UnnoY., UbagaiT., and OnoY.. 2018. Sub-minimum inhibitory concentrations of colistin and polymyxin B promote Acinetobacter baumannii biofilm formation. PLoS One, 13:e0194556.
55.
HeX., LuF., YuanF., JiangD., ZhaoP., ZhuJ., ChengH., CaoJ., and LuG.. 2015. Biofilm formation caused by clinical Acinetobacter baumannii isolates is associated with overexpression of the AdeFGH efflux pump. Antimicrob. Agents Chemother. 59:4817–4825.
56.
SagguS.K., JhaG., and MishraP.C.. 2019. Enzymatic degradation of biofilm by metalloprotease from microbacterium sp. Sks10. Front. Bioeng. Biotechnol. 7:192.
57.
HarperD.R., H.ParrachoM.R.T, WalkerJ., SharpR., HughesG., WerthénM., LehmanS., and MoralesS.. 2014. Bacteriophages and biofilms. Antibiotics, 3:270–284.
58.
TkhilaishviliT., LombardiL., KlattA.-B.B, TrampuzA., and Di LucaM.. 2018. Bacteriophage Sb-1 enhances antibiotic activity against biofilm, degrades exopolysaccharide matrix and targets persisters of Staphylococcus aureus. Int. J. Antimicrob. Agents, 52:842–853.
59.
KuipersS., RuthM.M, MientjesM., de SévauxR.G.L, and van IngenJ.. 2020. A Dutch case report of successful treatment of chronic relapsing urinary tract infection with bacteriophages in a renal transplant patient. Antimicrob. Agents Chemother. 64:e01281-19.
60.
UjmajuridzeA., ChanishviliN., GoderdzishviliM., LeitnerL., MehnertU., ChkhotuaA., KesslerT.M, and SybesmaW.. 2018. Adapted bacteriophages for treating urinary tract infections. Front. Microbiol. 9:1832.
61.
TrautnerB.W., and DarouicheR.O.. 2004. Role of biofilm in catheter-associated urinary tract infection. Am. J. Infect. Control, 32:177–183.
62.
WojciukB., SalaburaA., GrygorcewiczB., KędzierskaK., CiechanowskiK., and DołęgowskaB.. 2019. Urobiome: in sickness and in health. Microorganisms, 7:548.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
